Macitentan and pulmonary arterial hypertension

New England Journal of Medicine

Volumn 370, Issue 1, 2014, Pages 81-83

  Anderson, Timothy S ^a   Good, Chester B ^b   Gellad, Walid F ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MACITENTAN; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

HUMAN; LETTER; MEDICAL LITERATURE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK ASSESSMENT; RISK FACTOR; TREATMENT RESPONSE; FEMALE; HYPERTENSION, PULMONARY; MALE;

ENDOTHELIN A RECEPTOR ANTAGONISTS; ENDOTHELIN B RECEPTOR ANTAGONISTS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; PYRIMIDINES; SULFONAMIDES;

EID: 84892183230     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1313112     Document Type: Letter

References (4)

1. Pulido T, Adzerikho I, Channick R.N., et al Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;369:809-18.
2. Drazen JM, Curfman GD On authors and contributors. N Engl J Med 2002;347:55.
3. Ross JS, Hill KP, Egilman D.S., Krumholz HM Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA 2008;299:1800-12.
4. Blumenthal D, Campbell EG, Anderson M.S., Causino N., Louis KS Withholding research results in academic life science: evidence from a national survey of faculty. JAMA 1997;277: 1224-8.